Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 215, Issue 7, Pages 1913-1928Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20171960
Keywords
-
Categories
Funding
- National Research Foundation Singapore
- Singapore Ministry of Education under its Research Centres of Excellence initiative
- Terry Fox Foundation
- Ministry of Education Academic Research Fund Tier 1 grants [T1-2013, T1-2014]
Ask authors/readers for more resources
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of upstream signaling. Here, we demonstrate that the deubiquitinating enzyme USP28 functions through a feedback loop to destabilize RAF family members. Loss of USP28 stabilizes BRAF enhancing downstream MAPK activation and promotes resistance to RAF inhibitor therapy in culture and in vivo models. Importantly, we demonstrate that USP28 is deleted in a proportion of melanoma patients and may act as a biomarker for response to BRAF inhibitor therapy in patients. Furthermore, we identify Rigosertib as a possible therapeutic strategy for USP28-depleted tumors. Our results show that loss of USP28 enhances MAPK activity through the stabilization of RAF family members and is a key factor in BRAF inhibitor resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available